Research advances in proton beam therapy for hepatocellular carcinoma

DAI Shuyang,HUANG Xing,YANG Tian

DOI: https://doi.org/10.3969/j.issn.1001-5256.2013.10.006

2013-01-01

Abstract:Hepatocellular carcinoma( HCC),one of the most common malignancies with high prevalence and mortality rate,usually results in poor prognosis and limited survival. A comprehensive analysis on the number and location of tumors,Child- Pugh grade,and Barcelona Clinic Liver Cancer stage will help the development of suitable treatment programs and improve prediction of prognosis. A majority of patients are complicated by cirrhosis,enlarged tumor,multiple lesions,vascular invasion,and even cancer embolus in the portal vein. With the growth of knowledge about the radiation tolerance of normal tissue and the advances in radiotherapy techniques,radiotherapy has become an important tool for step- down therapy and adjuvant therapy for liver cancer. Proton beam therapy( PBT) is emerging as a novel radiotherapy for the management of HCC,which,benefiting from the effect of Bragg Peak from PBT,effectively decreases the toxicity of traditional radiotherapies to the liver and does little harm to the uninvolved liver tissue or the surrounding structures while intensifying the destruction in targeted malignant lesions. Furthermore,several previous studies on the treatment of HCC with PBT revealed excellent local control. The distinctive biophysical attributes of PBT in the treatment of HCC,as well as the available literature regarding clinical outcomes and toxicity of using PBT for HCC,are reviewed. Current evidence provides limited indications for PBT,which suggests that further study on the relationship between liver function and PBT is required to gain further insight into its indication and standardization.